The ORCA-3 trial mirrors the Phase 3 ORCA-2 trial and is designed to obtain additional safety and efficacy data.
- Placebo-controlled & double-blind
- 3 treatment arms: Placebo vs 6 or 12 weeks cytisinicline
Cytisinicline treatment for 6 or 12 weeks
- Does longer treatment lead to better efficacy?
- Does continued treatment prevent early relapses?
- Primary Endpoint: 4-week continuous abstinence ON treatment
- Follow up to 6 months
ORCA-3 Trial Locations
ORCA-3 is being conducted at the following locations in the US.
Aventiv Research, Inc.
614-501-6164 Ext. 2023
Accel Clinical Research
386-785-2400 Ext. 399
Altoona Center for Clinical Research
800-924-7790 ext. 188
MediSphere Medical Research Center, LLC
Insight Research Institute
Alliance For Multispecialty Research
(AMR Fort Myers)
Jacksonville Center for Clinical Research
Little Rock Allergy & Asthma Clinic
ActivMed Practices and Research
Clinical Research Associates, Inc.
615-329-0197 Ext. 231
Health Research of Hampton Roads, Inc.
Alliance for Multispecialty Research
Global Medical Institutes
609-921-3555 Ext. 110
Clinical Trials of Texas, LLC
Precision Clinical Research
Trial Management Associates, Inc.